Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more
Allogene Therapeutics Inc (ALLO) - Net Assets
Latest net assets as of September 2025: $315.33 Million USD
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has net assets worth $315.33 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($439.77 Million) and total liabilities ($124.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $315.33 Million |
| % of Total Assets | 71.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | -60.9% |
| 10-Year Change | N/A |
| Growth Volatility | 34.14 |
Allogene Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Allogene Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $422.18 Million | -17.58% |
| 2023-12-31 | $512.23 Million | -23.19% |
| 2022-12-31 | $666.88 Million | -27.92% |
| 2021-12-31 | $925.20 Million | -14.30% |
| 2020-12-31 | $1.08 Billion | +71.63% |
| 2019-12-31 | $629.02 Million | -10.54% |
| 2018-12-31 | $703.16 Million | +35158300.00% |
| 2017-12-31 | $-2.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allogene Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 181980000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $212.00K | 0.05% |
| Other Comprehensive Income | $-89.00K | -0.02% |
| Other Components | $2.24 Billion | 531.03% |
| Total Equity | $422.18 Million | 100.00% |
Allogene Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Allogene Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
$350.45 Million |
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
$350.58 Million |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
$350.61 Million |
|
Baotek Industrial Materials Ltd
TWO:5340
|
$350.61 Million |
|
Daqian Ecology & Landscape Co Ltd
SHG:603955
|
$350.31 Million |
|
Taiwan Shin Kong Security Co Ltd
TW:9925
|
$350.16 Million |
|
SoluM Co Ltd
KO:248070
|
$350.14 Million |
|
Voltalia S.A.
LSE:0QW7
|
$350.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allogene Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 512,233,000 to 422,179,000, a change of -90,054,000 (-17.6%).
- Net loss of 257,590,000 reduced equity.
- Share repurchases of 1,535,000 reduced equity.
- New share issuances of 112,047,000 increased equity.
- Other comprehensive income increased equity by 866,000.
- Other factors increased equity by 56,158,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-257.59 Million | -61.01% |
| Share Repurchases | $1.53 Million | -0.36% |
| Share Issuances | $112.05 Million | +26.54% |
| Other Comprehensive Income | $866.00K | +0.21% |
| Other Changes | $56.16 Million | +13.3% |
| Total Change | $- | -17.58% |
Book Value vs Market Value Analysis
This analysis compares Allogene Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $2.27 | x |
| 2018-12-31 | $7.84 | $2.27 | x |
| 2019-12-31 | $6.22 | $2.27 | x |
| 2020-12-31 | $8.97 | $2.27 | x |
| 2021-12-31 | $6.81 | $2.27 | x |
| 2022-12-31 | $4.66 | $2.27 | x |
| 2023-12-31 | $3.26 | $2.27 | x |
| 2024-12-31 | $2.17 | $2.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allogene Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1170863.64%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.30x
- Recent ROE (-61.01%) is below the historical average (-35.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.80K |
| 2018 | -30.08% | 0.00% | 0.00x | 1.10x | $-281.82 Million |
| 2019 | -29.35% | 0.00% | 0.00x | 1.14x | $-247.50 Million |
| 2020 | -21.63% | -608.87% | 0.03x | 1.14x | $-341.43 Million |
| 2021 | -26.46% | -636.12% | 0.04x | 1.14x | $-337.36 Million |
| 2022 | -49.46% | -135726.34% | 0.00x | 1.23x | $-396.50 Million |
| 2023 | -63.89% | -344489.47% | 0.00x | 1.25x | $-378.49 Million |
| 2024 | -61.01% | -1170863.64% | 0.00x | 1.30x | $-299.81 Million |
Industry Comparison
This section compares Allogene Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allogene Therapeutics Inc (ALLO) | $315.33 Million | 0.00% | 0.39x | $350.42 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |